Zusammenfassung
Frauen, die an einem Mammakarzinom behandelt wurden, leiden unter dem konsekutiven Östrogenmangel einer Chemo- oder antiendokrinen Therapie. Diese Frauen würden erheblich von einer Hormonsubstitution profitieren. Die Datenlage dazu ist allerdings inkonsistent. Zahlreiche Beobachtungsstudien konnten kein erhöhtes Rezidivrisiko unter Hormonersatztherapie (HRT) zeigen, allerdings waren viele dieser Arbeiten sehr heterogen, retrospektiv und hatten eine zu geringe Fallzahl. Die wenigen prospektiven Studien suggerieren eine Erhöhung des Rezidivrisikos unter HRT. Auch das Ovarialkarzinom ist ein hormonabhängiges Malignom, weshalb eine HRT in der Peri- und Postmenopause einen Einfluss auf das Erkrankungsrisiko haben kann, insbesondere nach behandelter Erkrankung. Die Datenlage zur Wirkung einer HRT auf das Ovarialkarzinom ist dünn. Epidemiologische Studien zeigen, dass eine langfristige HRT das Ovarialkarzinomrisiko möglicherweise erhöht. Noch spärlicher sind die Daten zum Einsatz einer HRT nach Ovarialkarzinombehandlung. Zuverlässige Empfehlungen lassen sich daraus nicht ableiten. Ziel dieser Arbeit ist es, aus der aktuellen Datenlage die Frage nach der Durchführbarkeit einer HRT zu eruieren und möglicherweise neue Empfehlungen daraus zu erhalten.
Abstract
Breast cancer patients undergoing chemotherapy or anti-endocrine treatment suffer from a subsequent lack of estrogen. While these women would benefit substantially by estrogen replacement, the pertinent data are sparse and inconsistent. Observational studies have not shown an increased risk of recurrence under hormone replacement therapy (HRT); however, the studies are heterogeneous, retrospective and mostly underpowered. The few randomized prospective studies suggest an increased recurrence rate with HRT regimens. Since ovarian cancer is a hormone-related malignancy as well, HRT in perimenopausal and postmenopausal women may have an impact on ovarian cancer risk, especially after primary treatment, but data are scanty. Epidemiological studies have shown that long-term HRT might even increase the risk of ovarian cancer The data on HRT after ovarian cancer treatment are even scantier ; thus, there are no reliable recommendations. This paper reviews the current literature concerning the feasibility of HRT in order to develop new recommendations.
Literatur
Allemand H, Seradour B, Weill A et al (2008) Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend. Bull Cancer (Paris) 95:11–15
Antoine C, Liebens F, Carly B et al (2007) Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review. Climacteric 10(1):23–26
Batur P, Blixen CE, Moore HC et al (2006) Menopausal hormone therapy (HT) in patients with breast cancer. Maturitas 53(2):123–132
Biglia N, Cozzarella M, Cacciari F et al (2003) Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 45(1):29–38
Biglia N, Mariani L, Marenco D et al (2006) Homone replacement therapy after gynaecological cancer. Gynakol Geburtshilfliche Rundsch 46(4):191–196
Canfell K, Banks E, Moa AM, Beral V (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188:641–644
Col NF, Hirota LK, Orr RK et al (2001) Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 19:2357–2363
Col NF, Kim JA, Chlebowski RT (2005) Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 7(4):R535–R540
Coughlin SS, Giustozzi A, Smith SJ, Lee NC (2000) A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 53:367–375
Eeles RA, Tan S, Witshaw E et al (1991) Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302:259–262
Emons G (2002) Hormonsubstitution nach Mammakarzinom. Gynäkologe 35:1114–1116
Garg PP, Kerlikowske K, Subak L, Grady D (1998) Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92:472–479
Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. und das Robert Koch Institut (2006) Krebs in Deutschland – Häufigkeiten und Trends. RoBo Print, Riegelsberg Saarbrücken
Gorins A, Espié M, Bedairia N et al (2006) Hormonal replacement therapy in menopause after breast cancer: first french study. Contracept Fertil Sex 26(10):696–699
Gorins A, Espie M, Bedairia N et al (2003) Hormone replacement therapy in breast cancer patients: a study of 230 patients, with a case-control study. Gynecol Obstet Fertil 31:614–619
Guidozzi F, Daponte A (1999) Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 86:1013–1018
Holli K, Isola J, Cuzick J (1998) Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16(9):3115–3120
Holmberg L, Anderson H (2004) HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 363:453–455
Holmberg L, Iversen OE, Rudenstam CM et al (2008) HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100(7):475–482. Erratum in: J Natl Cancer Inst 100(9):685
Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107:427–430
Katalinic A, Lemmer A, Zawinell A et al (2009) Trends in hormone therapy and breast cancer incidence – results from the German Network of Cancer Registries. Pathobiology 76(2):90–97
Marsden J, A’Hern R (2003) The Million Women Study and breast cancer. J Br Menopause Soc 9(3):95–97
Mascarenhas C, Lambe M, Bellocco R et al (2006) Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119(12):2907–2915
Mørch LS, Løkkegaard E, Andreasen AH et al (2009) Hormone therapy and ovarian cancer. JAMA 302(3):298–305
North American Menopause Society (2004) Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 11:11–33
Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674
Rodriguez C, Patel AV, Calle EE et al (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285:1460–1465
Rossing MA, Cushing-Haugen KL, Wicklund KG et al (2007) Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 16(12):2548–2556
Ursic-Vrscaj M, Bebar S, Zakelj MP (2001) Hormone replacement therapy after invasive ovarian serous cystoadenocarcinoma treatment: the effect on survival. Menopause 8:70–75
Vankrunkelsven P, Kellen E, Lousbergh D et al (2009) Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 118(2):425–432
Vassilopoulou-Sellin R, Klein MJ (1996) Estrogen replacement therapy after treatment for localized breast carcinoma. Patient responses and opinions. Cancer 78(5):1043–1048. Erratum in: Cancer 79(4):867
Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN et al (2002) Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 95:1817–1826
Von Schoultz E, Rutqvist LE, on behalf of the Stockholm Breast Cancer Study Group (2005) Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 97:533–535
Wernli KJ, Newcomb PA, Hampton JM et al (2008) Hormone therapy and ovarian cancer: incidence and survival. Cancer Causes Control 19(6):605–613
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thill, M., Fischer, D., Röder, K. et al. Hormonersatztherapie nach Mamma- und Ovarialkarzinom. Gynäkologische Endokrinologie 8, 35–40 (2010). https://doi.org/10.1007/s10304-009-0330-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10304-009-0330-9